Emerging use of nanoparticles in diagnosis and treatment of breast cancer

Lancet Oncology

Volumn 7, Issue 8, 2006, Pages 657-667

  Yezhelyev, Maksym V ^a   Gao, Xiaohu ^c   Xing, Yun ^b   Al Hajj, Ahmad ^a   Nie, Shuming ^b,d   O'Regan, Ruth M ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c University of Washington   (United States)

^d GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; CYCLIN D1; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DENDRIMER; DOCETAXEL; DOXORUBICIN; E1A PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; LIPOSOME; MACROGOL; MESSENGER RNA; METHOTREXATE; MYC PROTEIN; NANOPARTICLE; PACLITAXEL; PLATINUM DERIVATIVE; POLYETHYLENEIMINE; POLYGLACTIN; POLYMETHACRYLIC ACID; PROTEIN P53; QUANTUM DOT; SMALL INTERFERING RNA; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; UVOMORULIN; VINCA ALKALOID;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CARDIOTOXICITY; CHEMICAL STRUCTURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DOSE RESPONSE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; EARLY DIAGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL TOXICITY; GENE AMPLIFICATION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE IDENTIFICATION; HAND FOOT SYNDROME; HUMAN; IMMUNOHISTOCHEMISTRY; LIGHT SCATTERING; NANOTECHNOLOGY; NEUROPATHY; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVIEW; SYSTEMIC DISEASE; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEMS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LIPOSOMES; NANOSTRUCTURES; TUMOR MARKERS, BIOLOGICAL;

EID: 33746648133     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)70793-8     Document Type: Review

References (75)

1. Jain K. Nanotechnology in clinical laboratory diagnostics. Clin Chim Acta 358 (2005) 37-54
2. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5 (2005) 161-171
3. Yezhelyev M., Morris C., Gao X., et al. Multiple profiling of human breast cancer cell lines with quantum dots-Ab conjugates. Proc Am Assoc Cancer Res 46 (2005) 510 (abstr)
4. Jain K. Personalised medicine for cancer: from drug development into clinical practice. Expert Opin Pharmacother 6 (2005) 1463-1476
5. Chan P., Yuen T., Ruf F., et al. Method for multiplex cellular detection of mRNAs using quantum dot fluorescent in situ hybridization. Nucleic Acids Res 33 (2005) 161
6. Fortina P., Kricka L., Surrey S., et al. Nanobiotechnology: the promise and reality of new approaches to molecular recognition. Trends Biotechnol 23 (2005) 168-173
7. Gao X., Cui Y., Levenson R., et al. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 22 (2004) 969-976
8. Artemov D., Mori N., Okollie B., et al. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 49 (2003) 403-408
9. Batist G., Ramakrishman G., Rao C., et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19 (2001) 1444-1454
10. tm/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15 (2004) 440-449
11. Gradishar W., Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23 (2005) 7794-7803
12. Ibrahim N., Samuels B., Page R., et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23 (2005) 6019-6026
13. Park J W. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 4 (2002) 95-99
14. Hofheinz R., Gnad-Vogt S., Beyer U., et al. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 16 (2005) 691-707
15. Lee C., MacKay J., Frechet J., and Szoka F. Designing dendrimers for biological applications. Nat Biotechnol 23 (2005) 1517-1526
16. Svenson S., and Tomalia D. Dendrimers in biomedical applications: reflections on the field. Adv Drug Deliv Rev 57 (2005) 2106-2129
17. Tasis D., Tagmatarchis N., Bianco A., and Prato M. Chemistry of carbon nanotubes. Chem Rev 106 (2006) 1105-1136
18. Bianco A., Kostarelos K., and Prato M. Applications of carbon nanotubes in drug delivery. Curr Opin Chem Biol 9 (2005) 674-679
19. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2 (2003) 347-360
20. Wu X., Liu H., Liu J., et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 21 (2003) 41-46
21. Lidke D., Nagy P., Heintzmann R., et al. Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nat Biotechnol 22 (2004) 198-203
22. Gao X., Yang L., Petros J., et al. In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol 16 (2005) 63-72
23. Medintz I., Uyeda H., Goldman E., and Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater 4 (2005) 435-446
24. Yezhelyev M., Morris C., Gao X., et al. Simultaneous and quantitative detection of multiple biomarkers in human breast cancers using semiconductor multicolor quantum dots breast cancer research and treatment. Breast Cancer Res Treat 94 suppl (2005) S48
25. Yezhelyev M., Gao X., Markus A., et al. Multiplex molecular diagnostic of tumor tissue using quantum dots. Proc Am Soc Clin Oncol 23 (2005) 843 (abstr)
26. Hardman R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ Health Perspect 114 (2006) 165-172
27. Doering W., and Nie S. Spectroscopic tags using dye-embedded nanoparticles and surface-enhanced Raman scattering. Anal Chem 75 (2003) 6171-6176
28. Moore B., Stevenson L., Watt A., et al. Rapid and ultra-sensitive determination of enzyme activities using surface-enhanced resonance Raman scattering. Nat Biotechnol 22 (2004) 1133-1138
29. Faulds K., Smith W., Graham D., and Lacey R. Assessment of silver and gold substrates for the detection of amphetamine sulfate by surface enhanced Raman scattering (SERS). Analyst 127 (2002) 282-286
30. Zhao M., Beauregard D., Loizou L., et al. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med 11 (2001) 1241-1244
31. Perez O., and Nolan G. Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry. Nat Biotechnol 20 (2002) 155-162
32. Kircher M., Mahmood U., King R., et al. Multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 63 (2003) 8122-8125
33. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
34. Vogel C., Cobleigh M., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 719-726
35. Konecny G., Pauletti G., Pegram M., et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95 (2003) 142-153
36. Elledge R., Green S., Pugh R., et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 89 (2000) 111-117
37. Biesterfeld S., Kraus H., Reineke T., et al. Analysis of the reliability of manual and automated immunohistochemical staining procedures. A pilot study. Anal Quant Cytol Histol 25 (2003) 90-96
38. Jaiswal J., and Simon S. Potentials and pitfalls of fluorescent quantum dots for biological imaging. Trends Cell Biol 14 (2004) 497-504
39. Jaiswal J., Mattoussi H., Mauro J., and Simon S. Long-term multiple color imaging of live cells using quantum dot bioconjugates. Nat Biotechnol 21 (2003) 47-51
40. Han M., Gao X., Su J., and Nie S. Quantum-dot-tagged microbeads for multiplexed optical coding of biomolecules. Nat Biotechnol 19 (2001) 631-635
41. Giepmans B., Deerinck T., Smarr B., et al. Correlated light and electron microscopic imaging of multiple endogenous proteins using quantum dots. Nat Methods 2 (2005) 743-749
42. Al-Hajj A., Yezhelyev M., Gao X., et al. Simultaneous, quantitative detection of multiple biomarkers in human breast cancers using semiconductor multicolor quantum dots. Proc Am Assoc Cancer Res 47 (2006) 3587 (abstr)
43. Xiao Y., and Barker P. Semiconductor nanocrystal probes for human metaphase chromosomes. Nucleic Acids Res 32 (2004) E28
44. Xiao Y., Telford W., Ball J., et al. Semiconductor nanocrystal conjugates, FISH and pH. Nat Methods 2 (2005) 723
45. Rabin O., Manuel Perez J., Grimm J., et al. An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat Mater 5 (2006) 118-122
46. Will O., Purkayastha S., Chan C., et al. Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis. Lancet Oncol 7 (2006) 52-60
47. Ito A., Shinkai M., Honda H., and Kobayashi T. Medical application of functionalized magnetic nanoparticles. J Biosci Bioeng 100 (2005) 1-11
48. Weissleder R., Hahn P., Stark D., et al. Superparamagnetic iron oxide: enhanced detection of focal splenic tumors with MR imaging. Radiology 169 (1988) 399-403
49. Akerman M., Chan W., Laakkonen P., et al. Nanocrystal targeting in vivo. Proc Natl Acad Sci USA 99 (2002) 12617-12621
50. Stroh M., Zimmer J., Duda D., et al. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat Med 11 (2005) 678-682
51. Voura E., Jaiswal J., Mattoussi H., and Simon S. Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy. Nat Med 10 (2004) 993-998
52. Kim S., Lim Y., Soltesz E., et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol 22 (2004) 93-97
53. Cody S. Clinical aspects of sentinel node biopsy. Breast Cancer Res 3 (2001) 104-108
54. Bonnema J., and van de Velde C. Sentinel lymph node biopsy in breast cancer. Ann Oncol 13 (2002) 1531-1537
55. Komenaka I., Bauer V., Schnabel F., et al. Allergic reactions to isosulfan blue in sentinel lymph node mapping. Breast J 11 (2005) 70-72
56. Ciatto S. Sentinel lymph node biopsy: sentinel node technique has drawbacks. BMJ 329 (2004) 170
57. Hirsch L., Stafford R., Bankson J., et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA 100 (2003) 13549-13554
58. Slamon D., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
59. Romond E., Perez E., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
60. Theodoulou M., Campos S., Batist G., et al. TLC D99 (Myocet) and Herceptin is safe in advanced breast cancer: final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol 21 (2002) 55a (abstr)
61. Gelderblom H., Verweij, Nooter K., et al., Cremaphor E. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37 (2001) 1590-1598
62. Weiss R., Donehower R., Wiernik P., et al. Hypersensitivity reactions from Taxol. J Clin Oncol 8 (1990) 1263-1268
63. Sparreboom A., Scripture C., Trieu V., et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 11 (2005) 4136-4143
64. O'Shaughnessy J., Blum J., Sandbach J., et al. Weekly nanoparticle albumin paclitaxel (Abraxane) results in long-term disease control in patients with taxane-refractory metastatic breast cancer. Breast Cancer Res Treat 88 (2004) S65 (abstr 1070)
65. Shenoy D., and Amiji M. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm 293 (2005) 261-270
66. Takahashi S., Ito Y., Hatake K., and Sugimoto Y. Gene therapy for breast cancer: review of clinical gene therapy trials for breast cancer and MDR1 gene therapy trial in Cancer Institute Hospital. Breast Cancer 13 (2006) 8-15
67. Osborne C., Wilson P., and Tripathy D. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist 9 (2004) 361-377
68. Hayes M., Drummond D., Kirpotin D., et al. Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery. Gene Ther 13 (2006) 646-651
69. Hortobagyi G., Ueno N., Xia W., et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 19 (2001) 3422-3433
70. Yan D., Chang L., and Hung M. Repressed expression of the HER-2/c-erbB-2 proto-oncogene by the adenovirus E1a gene products. Oncogene 6 (1991) 343-345
71. Prabha S., and Labhasetwar V. Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells. Mol Pharm 1 (2004) 211-219
72. Menendez J., Vellon L., Colomer R., and Lupu R. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Int J Cancer 115 (2005) 19-35
73. Choudhury A., Charo J., Parapuram S., et al. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 108 (2004) 71-77
74. Schwab G., Chavany C., Duroux I., et al. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc Natl Acad Sci USA 91 (1994) 10460-10464
75. Urban-Klein B., Werth S., Abuharbeid S., et al. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 12 (2005) 461-466